12-Month Lobbying Summary - In-house Corporation

Return to 12-Month Lobbying Activity Search Results

Moderna Biopharma Canada Corporation / Stefan Raos, General Manager, Canada

Registration Summary

Active - Last Updated: 2026-01-01

Who is lobbying?

Moderna Biopharma Canada Corporation (Address & business activities)

Stefan Raos, General Manager, Canada

Received government funding or funding expected in current financial year

Yes

Business Relationships

Moderna Biopharma Canada Corporation is a subsidiary of the following parent companies

Moderna TX, Inc. (Address information)

Beneficiaries of the Lobbying Activity

Moderna Biopharma Canada Corporation has the following subsidiaries that could have a direct interest in the outcome of the undertaking

Moderna Manufacturing Canada Corp. (Address information)

What is being lobbied?

Subject Matter Details

Details Regarding the Identified Subject Matter
Subject matters	Details	Categories
Research and Development, Science and Technology	Government policies regarding innovation, research and development, and messenger ribonucleic acid (mRNA) biotechnology	Policies or Program
Government Procurement, Health	Health Canada and Public Services and Procurement Canada policies regarding the development, procurement, and distribution of Moderna’s COVID-19 vaccine to various segments of the population, including future distribution models	Policies or Program
Economic Development, Health	The government’s Pandemic Preparedness Strategy as it relates to the corporation’s future operations in Canada	Policies or Program

Who is being lobbied?

Government Institutions

Federal Economic Development Agency for Southern Ontario (FedDev)
Global Affairs Canada (GAC)
Health Canada (HC)
House of Commons
Innovation, Science and Economic Development Canada (ISED)
Prairies Economic Development Canada (PrairiesCan)
Privy Council Office (PCO)
Public Health Agency of Canada (PHAC)
Public Services and Procurement Canada (PSPC)
Treasury Board Of Canada Secretariat (TBS)

Communication techniques

Communication techniques that have been used or are expected to be used in the course of the undertaking:

Oral communication
Written communication

Who are the lobbyists?

Senior officers whose lobbying activities represent less than a significant part of their duties

Stefan Raos, General Manager | No public offices held

Senior officers and employees whose lobbying activities represent a significant part of their duties

Laura Fitzgerald, Associate Director, External Affairs | No public offices held
Patricia Gauthier, General Manager, Resilience Program and Markets | No public offices held
Leslie Madden, Federal Affairs & Policy Lead | No public offices held
James Mansi, VP and Head, Medical Strategy, Resilience Markets & CMD Canada | No public offices held
Roger Ngassam, Site Head, Canada | No public offices held
Rahbar Rahimpour, Director, R&D Strategic Alliances | No public offices held
Lisa Wise-Milestone, Associate Director, Strategic Partnerships | No public offices held

Lobbyists in previous versions
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Laura Fitzgerald, Associate Director, External Affairs | No public offices held
- Patricia Gauthier, General Manager, Resilience Program and Markets | No public offices held
- Leslie Madden, Federal Affairs & Policy Lead | No public offices held
- James Mansi, VP and Head, Medical Strategy, Resilience Markets & CMD Canada | No public offices held
- Roger Ngassam, Site Head, Canada | No public offices held
- Rahbar Rahimpour, Director, R&D Strategic Alliances | No public offices held
- Stefan Raos, General Manager | No public offices held
- Lisa Wise-Milestone, Associate Director, Strategic Partnerships | No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Laura Fitzgerald, Associate Director, External Affairs | No public offices held
- Patricia Gauthier, General Manager, Resilience Program and Markets | No public offices held
- Leslie Madden, Federal Affairs & Policy Lead | No public offices held
- James Mansi, VP and Head, Medical Strategy, Resilience Markets & CMD Canada | No public offices held
- Roger Ngassam, Site Head, Canada | No public offices held
- Rahbar Rahimpour, Director, R&D Strategic Alliances | No public offices held
- Lisa Wise-Milestone, Associate Director, Strategic Partnerships | No public offices held

Registration number: 956349-370107
View all registrations versions

Monthly Communication Reports

What oral and arranged communications have taken place?

Date	DPOH, Position Title \| Government Institution	Subject Matters
2026-02-11	David McFarlane, Director of Policy \| Minister of Industry and Minister Responsible for Canada Economic Development for Quebec Regions, Innovation, Science and Economic Development Canada (ISED) Manuela Tomic, Senior Policy Advisor \| Minister of Industry and Minister Responsible for Canada Economic Development for Quebec Regions, Innovation, Science and Economic Development Canada (ISED)	Research and Development, Science and Technology
2025-11-21	Ritu Banerjee, Assistant Deputy Minister \| Director General's Office, Innovation, Science and Economic Development Canada (ISED)	Economic Development, Health, Research and Development, Science and Technology
2025-11-05	Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions Innovation, Science and Economic Development Canada (ISED)	Economic Development, Health, Research and Development, Science and Technology
2025-09-19	Ritu Banerjee, Assistant Deputy Minister \| Director General's Office, Innovation, Science and Economic Development Canada (ISED) Natasha Crowcroft, Vice President Public Health Agency of Canada (PHAC) Andrea Gilpin, Chief of Staff Public Health Agency of Canada (PHAC) Nancy Hamzawi, President Public Health Agency of Canada (PHAC) Philip Jennings, Deputy Minister \| Office of the Deputy Minister, Innovation, Science and Economic Development Canada (ISED) Mélanie Joly, Minister of Innovation, Sciences and Economic Development Innovation, Science and Economic Development Canada (ISED) Marjorie Michel, Minister of Health Public Health Agency of Canada (PHAC)	Economic Development, Government Procurement, Health, Research and Development, Science and Technology
2025-09-02	Andrea Andrachuk, Director General Public Services and Procurement Canada (PSPC) Heather Deehan, Director Public Health Agency of Canada (PHAC) Andrea Gilpin, Chief of Staff Public Health Agency of Canada (PHAC)	Economic Development, Government Procurement, Health
2025-08-26	Ritu Banerjee, Assistant Deputy Minister \| Director General's Office, Innovation, Science and Economic Development Canada (ISED)	Research and Development, Science and Technology
2025-08-20	David McFarlane, Director Of Policy Innovation, Science and Economic Development Canada (ISED) Manuela Tomic, Senior Policy Advisor Innovation, Science and Economic Development Canada (ISED)	Economic Development, Health, Research and Development, Science and Technology
2025-07-31	Pierre Paul-Hus, Member of Parlliament House of Commons	Economic Development, Health, Research and Development, Science and Technology

View all monthly communication reports

Return to 12-Month Lobbying Activity Search Results

Moderna Biopharma Canada Corporation - Address & business activities

Address:

155 Wellington St W
Suite 3130
Toronto, ON M5V 3H1
Canada

Telephone number: 647-503-0703

Contact information in previous versions
- 666 Burrard Street
  Suite 1700, Park Place
  Vancouver, BC V6C 2X8
  Canada
  
  Telephone number: 647-503-0703
- 666 Burrard Street
  Suite 1700, Park Place
  Vancouver, BC V6C 2X8
  Canada
  
  Telephone number: 416-859-0079

Description of activities:
Moderna is a biotech company focusing on vaccine technologies. We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured.

Descriptions of the corporation's activity in previous versions:
- Moderna is an American biotech company focusing on vaccine technologies. We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured.

End date of the last completed financial year: 2025-12-31

List of Government Funding
Government Institution	Funding Received in Last Financial Year	Funding Expected in Current Financial Year
Investissement Quebec	$3,737,014.00	No
Ministry of Economic Development, Job Creation and Trade	No	Yes

Government funding in previous versions

List of Government Funding
End date of the last completed financial year	Government Institution	Funding Received in Last Financial Year	Funding Expected in Current Financial Year
2024-12-31	Investissement Quebec	$18,637,142.00	Yes
2024-12-31	Ministry of Economic Development, Job Creation and Trade	No	Yes

Search and menus

Language selection

12-Month Lobbying Summary - In-house Corporation

Moderna Biopharma Canada Corporation / Stefan Raos, General Manager, Canada

Who is lobbying?

Moderna Biopharma Canada Corporation (Address & business activities)

Received government funding or funding expected in current financial year

Business Relationships

Moderna Biopharma Canada Corporation is a subsidiary of the following parent companies

Beneficiaries of the Lobbying Activity

Moderna Biopharma Canada Corporation has the following subsidiaries that could have a direct interest in the outcome of the undertaking

What is being lobbied?

Subject Matter Details

Who is being lobbied?

Government Institutions

Communication techniques

Who are the lobbyists?

Senior officers whose lobbying activities represent less than a significant part of their duties

Senior officers and employees whose lobbying activities represent a significant part of their duties

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

What oral and arranged communications have taken place?

12-Month Lobbying Summary - In-house Corporation

Moderna Biopharma Canada Corporation / Stefan Raos, General Manager, Canada

Moderna Biopharma Canada Corporation (Address & business activities)

Received government funding or funding expected in current financial year

Business Relationships

Moderna Biopharma Canada Corporation is a subsidiary of the following parent companies

Beneficiaries of the Lobbying Activity

Moderna Biopharma Canada Corporation has the following subsidiaries that could have a direct interest in the outcome of the undertaking

Subject Matter Details

Government Institutions

Communication techniques

Senior officers whose lobbying activities represent less than a significant part of their duties

Senior officers and employees whose lobbying activities represent a significant part of their duties

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Moderna Biopharma Canada Corporation - Address & business activities

Moderna Manufacturing Canada Corp.

Moderna TX, Inc.